Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory-Reference-Cited by-同舟云学术

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory

Published:2012-10-31 Issue:6 Volume:27 Page:690-697
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:Fundam Clin Pharmacol

Author:

Bouchet Stéphane¹²³,Titier Karine³,Moore Nicholas¹²³,Lassalle Régis¹,Ambrosino Basmah¹,Poulette Sylvie¹,Schuld Peter⁴,Belanger Coralie⁵,Mahon François-Xavier¹³⁶,Molimard Mathieu¹²³

Affiliation:

1. Univ Bordeaux; F-33000 Bordeaux France

2. INSERM U657; F-33000 Bordeaux France

3. CHU Bordeaux; F-33000 Bordeaux France

4. Novartis Pharma SpA; Origgio Italy

5. Novartis Pharma SA; Rueil-Malmaison France

6. INSERM U1035; F-33000 Bordeaux France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/fcp.12007/fullpdf

Reference22 articles.

1. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS);Hughes;Blood,2010

2. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS]);Guilhot;ASH Annual Meeting Abstracts,2008

3. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study;Larson;Blood,2008

4. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia;Picard;Blood,2007

5. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia;Takahashi;Clin. Pharmacol. Ther.,2010

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

2. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients;Pharmaceutics;2024-06-19

3. Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?;Expert Review of Clinical Pharmacology;2024-02-12

4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

5. Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study;The Journal of Clinical Pharmacology;2023-09